The peptide BPC 157 attenuated or completely eliminated the consequences of inferior caval vein ligation in rats, including thrombosis, vein injury, and hemodynamic disturbances.
All consequences counteractedBPC 157 largely attenuated or completely eliminated thrombosis, bleeding, vein injury, and hemodynamic disturbances from vein ligation
What the researchers found
BPC 157 administered at doses of 10 μg or 10 ng/kg counteracted virtually all consequences of inferior caval vein ligation in rats. Direct vein injury, thrombosis, thrombocytopenia, and prolonged bleeding were all counteracted. The peptide promoted rapid formation of collateral blood vessels and redistribution of trapped blood volume through alternative venous pathways.
Hemodynamic disturbances including venous hypertension, arterial hypotension, and tachycardia were counteracted. BPC 157-treated rats showed raised plasma nitric oxide values but normal MDA (oxidative stress marker) values. In vein tissue, the peptide reversed low NO values and counteracted elevated MDA levels. Gene expression changes were observed in EGR, NOS, SRF, VEGFR, and KRAS across multiple veins.
Why it matters
Venous thrombosis is a major clinical problem with limited treatment options beyond anticoagulants, which carry bleeding risks. This study suggests BPC 157 could address multiple aspects of venous disease simultaneously — thrombosis, vessel injury, hemodynamic disturbances, and oxidative stress — through a single peptide therapy, while also promoting the body's own compensatory mechanisms like collateral vessel formation.
How the study worked
Rats underwent inferior caval vein ligation up to the right ovarian vein to model Virchow's triad (vessel injury, stasis, thrombosis). BPC 157 was administered as either an early or delayed therapy regimen. Assessment included microcamera gross examination, microscopy, venography, bleeding time, blood pressure monitoring, ECG, thermography, plasma MDA and NO levels, tissue markers, and gene expression analysis via RT-PCR.
What this study cannot tell us
This is an animal study in rats, and results may not translate to humans. BPC 157 is not approved for human use by any regulatory agency. The abstract does not provide specific statistical comparisons or group sizes. The study comes from the Sikirić group, which produces the majority of BPC 157 research, and independent replication by other laboratories would strengthen the findings. Specific mechanisms of action remain incompletely characterized.
How to read the evidence
This is a preclinical animal study using a well-characterized rat model of venous thrombosis. While it includes comprehensive multi-parameter assessment (imaging, hemodynamics, molecular markers, gene expression), it lacks human data and independent replication.
When this study was published
Published in 2018, this study is part of the ongoing body of BPC 157 research. Its findings remain relevant as interest in this peptide continues to grow, though no human clinical trials have followed.
The bigger picture
BPC 157 research has consistently shown broad protective effects across various tissue injury models. This study extends those findings to venous thromboembolism, a condition that affects millions worldwide. The peptide's ability to simultaneously promote collateral vessel formation, normalize hemodynamics, and modulate oxidative stress markers suggests it acts through multiple complementary pathways rather than a single mechanism.
Questions still open
- Could BPC 157's vascular protective effects translate to human venous thromboembolism prevention or treatment?
- What are the specific molecular pathways by which BPC 157 promotes collateral vessel formation so rapidly?
- How does BPC 157's anti-thrombotic action compare to conventional anticoagulant therapies in terms of bleeding risk?
Common questions
What is BPC 157 and where does it come from?
How did BPC 157 help with blood clots in this study?
Read the original research
Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157.
Vascular pharmacology, 106, 54-66
Citation
Vukojević, Jakša; Siroglavić, Marko; Kašnik, Katarina; Kralj, Tamara; Stanćić, Duje; Kokot, Antonio; Kolarić, Darko; Drmić, Domagoj; Sever, Anita Zenko; Barišić, Ivan; Šuran, Jelena; Bojić, Davor; Patrlj, Masa Hrelec; Sjekavica, Ivica; Pavlov, Katarina Horvat; Vidović, Tinka; Vlainić, Josipa; Stupnišek, Mirjana; Seiwerth, Sven; Sikirić, Predrag. (2018). Rat inferior caval vein (ICV) ligature and particular new insights with the stable gastric pentadecapeptide BPC 157.. Vascular pharmacology, 106, 54-66. https://doi.org/10.1016/j.vph.2018.02.010